文献速递中医内科中药与中成药合理使用针灸推拿

术后肠麻痹与术后胃肠功能障碍:发病机制及结直肠加速康复外科方案之外的新治疗策略

Postoperative Ileus and Postoperative Gastrointestinal Tract Dysfunction: Pathogenic Mechanisms and Novel Treatment Strategies Beyond Colorectal Enhanced Recovery After Surgery Protocols.
PubMed 文献 · Front Pharmacol · 2020-11-24

本文为叙述性综述,聚焦术后肠麻痹(POI)与术后胃肠功能障碍(POGD)的发病机制及在研治疗策略。机制涉及手术操作与创伤、神经炎症、反应性肠胶质细胞及多种免疫细胞。尽管结直肠加速康复外科(ERAS)已实施,POI与POGD仍是重大医疗问题,在研疗法包括5HT4R激动剂、迷走神经刺激、针灸、草药、外周阿片拮抗剂等。

要点

  • POI与POGD的机制涉及手术创伤、神经炎症、反应性肠胶质细胞及免疫细胞相互作用。
  • 结直肠ERAS方案可保护对抗POI与POGD,但问题仍然显著。
  • 在研策略包括5HT4R激动剂、迷走神经刺激、针灸、草药、外周阿片拮抗剂等。

核心结论

  • 需更好理解POI与POGD的短期和长期结局相关机制,才能开发更好的预防和治疗策略。

研究设计与样本

  • 叙述性综述,聚焦POI与POGD发病机制的最新概念及在研药物或治疗方法。

主要发现

  • 机制涉及肠道手术操作与手术创伤、神经炎症、反应性肠胶质细胞、巨噬细胞、肥大细胞、单核细胞、中性粒细胞及ICC。
  • 免疫、炎症、神经和胶质细胞之间的精确相互作用尚不完全清楚。
  • 反应性肠胶质细胞是新兴治疗靶点,正在肠神经病、胃肠动力障碍和POI中深入研究。
  • 尽管实施结直肠ERAS,POI与POGD仍是重大医疗问题及医疗系统负担。
  • Clin.Trials.gov列出超过100种在研药物或治疗,包括5HT4R激动剂(Prucalopride和TAK 954)、迷走神经刺激ENS-巨噬细胞nAChR胆碱能通路、针灸、草药、外周阿片拮抗剂(Alvimopen、Methlnaltexone、Naldemedine)、抗腹胀/排气药物(Simethiocone)、饥饿素促动力激动剂(Ulimovelin)、饮用咖啡及尼古丁口香糖。

临床怎么用

  • 临床可继续实施结直肠ERAS方案以保护对抗POI与POGD。
  • 关注在研的5HT4R激动剂、外周阿片拮抗剂、针灸、草药等策略,但需更多证据支持其常规使用。

局限性

  • 免疫、炎症、神经和胶质细胞之间的精确相互作用尚不完全清楚。
  • 需更好理解POI与POGD的短期和长期结局相关机制,才能开发更好的预防和治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Postoperative ileus (POI) and postoperative gastrointestinal tract dysfunction (POGD) are well-known complications affecting patients undergoing intestinal surgery. GI symptoms include nausea, vomiting, pain, abdominal distention, bloating, and constipation. These iatrogenic disorders are associated with extended hospitalizations, increased morbidity, and health care costs into the billions and current therapeutic strategies are limited. This is a narrative review focused on recent concepts in the pathogenesis of POI and POGD, pipeline drugs or approaches to treatment. Mechanisms, cellular targets and pathways implicated in the pathogenesis include gut surgical manipulation and surgical trauma, neuroinflammation, reactive enteric glia, macrophages, mast cells, monocytes, neutrophils and ICC's. The precise interactions between immune, inflammatory, neural and glial cells are not well understood. Reactive enteric glial cells are an emerging therapeutic target that is under intense investigation for enteric neuropathies, GI dysmotility and POI. Our review emphasizes current therapeutic strategies, starting with the implementation of colorectal enhanced recovery after surgery protocols to protect against POI and POGD. However, despite colorectal enhanced recovery after surgery, it remains a significant medical problem and burden on the healthcare system. Over 100 pipeline drugs or treatments are listed in Clin.Trials.gov. These include 5HT4R agonists (Prucalopride and TAK 954), vagus nerve stimulation of the ENS-macrophage nAChR cholinergic pathway, acupuncture, herbal medications, peripheral acting opioid antagonists (Alvimopen, Methlnaltexone, Naldemedine), anti-bloating/flatulence drugs (Simethiocone), a ghreline prokinetic agonist (Ulimovelin), drinking coffee, and nicotine chewing gum. A better understanding of the pathogenic mechanisms for short and long-term outcomes is necessary before we can develop better prophylactic and treatment strategies.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Mazzotta E, Villalobos-Hernandez EC, Fiorda-Diaz J, et al. Postoperative Ileus and Postoperative Gastrointestinal Tract Dysfunction: Pathogenic Mechanisms and Novel Treatment Strategies Beyond Colorectal Enhanced Recovery After Surgery Protocols. Front Pharmacol. 2020. PMID: 33390950. doi:10.3389/fphar.2020.583422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。